You are here » Home » Companies » Company Overview » Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd.

BSE: 500660 Sector: Health care
NSE: GLAXO ISIN Code: INE159A01016
BSE 00:00 | 03 Dec 1732.10 37.80
(2.23%)
OPEN

1698.00

HIGH

1752.30

LOW

1698.00

NSE 00:00 | 03 Dec 1731.05 39.10
(2.31%)
OPEN

1705.70

HIGH

1752.00

LOW

1705.70

OPEN 1698.00
PREVIOUS CLOSE 1694.30
VOLUME 11412
52-Week high 1824.65
52-Week low 1379.00
P/E 57.47
Mkt Cap.(Rs cr) 29,344
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1698.00
CLOSE 1694.30
VOLUME 11412
52-Week high 1824.65
52-Week low 1379.00
P/E 57.47
Mkt Cap.(Rs cr) 29,344
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) - Chairman Speech

Company chairman speech

Dear Shareholders

2020 was an extraordinary and challenging year for all of us. Despite the challengesyour Company remained resilient and focussed on our strategic priorities. Our endeavourwas to improve the quality of human life by helping people do more feel better and livelonger.

Over the course of the year our learnings and investments in people and technologygave us an opportunity to enhance access to our focus brands and prepare us for futureproduct launches. Our business continuity measures ensured consistent growth of our focusbrands with Augmentin Betnovate Calpol Ceftum and Synflorix featuring amongthe top brands in the Indian Pharmaceuticals Market (IPM).

Your Company also continued to lead the private market in the vaccines segment with itsdiversified portfolio to protect children adolescents and adults. Despite the headwindscaused by COVID-19 the vaccines business bounced back to pre-COVID performance in thelast quarter of 2020. Your Company launched the tetravalent influenza Northern Hemispherevaccine (Fluarix Tetra NH 2020-21) in September 2020 and garnered 35% volume sharewithin three months of launch taking the second position in a market occupied by fourbrands.

Equally innovation for healthcare impact is at the heart of what we do in Indiaexemplified by the recent launch of biologic for Severe Eosinophilic Asthma – Nucala.To further enable treatment continuity owing to restrictions and challenges faced bypatients due to the pandemic your Company launched "Nucala home administrationprogramme". This initiative has been a huge saviour for patients during these times.

While your Company's patient-centric approach remained unshakeable as ever we alsoprioritised those who make the realisation of our purpose possible – our employees– as we continued to support them with various initiatives focussing on their healthand wellbeing. During the lockdown your Company focussed on skill enhancement ofemployees – particularly the field-force – to give them a competitive edge inthe ‘new normal' business context.

The pandemic has revealed opportunities to partner with governments and help supportthe national health goals of India. Your Company's parent organisation GSK plc hasentered into an in-principle global partnership with Novavax to produce up to 60 milliondoses of the COVID-19 vaccine. It is also working with Sanofi and Medicago to harness theadjuvant technology in developing COVID-19 vaccines while also collaborating with CureVacto develop mRNA vaccines which have the potential to address multiple COVID-19 variantsthat are emerging across the world.

Your Company has shown remarkable agility and resilience throughout the year inunprecedented circumstances. This has included hundreds of colleagues who have continuedto work in the Nashik manufacturing site throughout the pandemic to ensure that vitalmedicines continued to be manufactured so as to reach patients.

I want to thank our remarkable workforce and our partners for without them we wouldhave not succeeded.

R.S. Karnad

.